Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen clinical trials

A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5

This 40-week study looks at two different insulin-based treatments for adults with type 2 diabetes that isn't well-controlled. It compares a new once-weekly injection (IcoSema) with an existing daily or twice-daily insulin (Ryzodeg) to see which is more effective and safer.